Garcos Pharmaceutical Group Co., Ltd. is committed to providing patients with breakthrough treatment solutions. The company's vision is to work hand in hand with partners to become a globally recognized leader in drug development. The company's laboratories are located in Beijing, China and Massachusetts, USA, and the experimental platforms have the technology to develop modified inhibitors of protein phosphatase, KRAS, and other transcription factors. Gacos has received investments from several biotechnology-specialized investment institutions, including Qiming Ventures, Lilly Asia Fund, Gao Lin, and Taiwan's Yu Sheng.
No Data
No Data